Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · see citing works

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747 · see citing works

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works

Somatic Activation of KIT in Distinct Subtypes of Melanoma

Curtin, J. A., BUSAM, K. J., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,612 · see citing works

Whole-genome landscapes of major melanoma subtypes

Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,466 · see citing works

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179 · see citing works

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · see citing works

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works

KIT as a Therapeutic Target in Metastatic Melanoma

Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 886 · see citing works

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 685 · see citing works

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

D’Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J. C., Hodi, F. S., Lorigan, P. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9258 · Cited by 653 · see citing works

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Beadling, C., Jacobson‐Dunlop, E., Hodi, F. S., Le, C., Warrick, A., Patterson, J., Town, A., Harlow, A., Cruz, F., Azar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0575 · Cited by 645 · see citing works

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

Hodi, F. S., Corless, C. L., Giobbie‐Hurder, A., Fletcher, J. A., Zhu, M. J., Mariño‐Enríquez, A., Friedlander, P. A., Gonzalez, R. C., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 606 · see citing works

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

Chi, Z., Li, S., Sheng, X., Si, L., Cui, C., Han, M., & Guo, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-85 · Cited by 386 · see citing works

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370 · see citing works

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo

Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita∥, H., & Nakajima, Y. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12069 · Cited by 277 · see citing works

How well do Medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems?

Newell, S., Sanson‐Fisher, R., Girgis, A., & Bonaventura, A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8 · Cited by 276 · see citing works

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors

Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270 · see citing works

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

Si, L., Kong, Y., Xu, X., Flaherty, K. T., Sheng, X., Cui, C., Chi, Z., Li, S., Mao, L., & Guo, J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.056 · Cited by 254 · see citing works

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Kong, Y., Si, L., Zhu, Y., Xu, X., Corless, C. L., Flaherty, K. T., Li, L., Li, H., Sheng, X., Cui, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2346 · Cited by 250 · see citing works

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients

Lian, B., Cui, C.-L., Zhou, L., Song, X., Zhang, X. S., Wu, D., Si, L., Chi, Z., SHENG, X. N., Mao, L. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw694 · Cited by 176 · see citing works

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Mao, L., Lian, B., Bai, X., Wang, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0693-2 · Cited by 169 · see citing works

Ipilimumab for Patients With Advanced Mucosal Melanoma

Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N. H., Panageas, K. S., Lawrence, D. P., Ibrahim, N., Flaherty, K. T., Sullivan, R. J., Ott, P. A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0464 · Cited by 165 · see citing works

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Vecchio, M. D., Guardo, L. D., Ascierto, P. A., Grimaldi, A. M., Chiarion‐Sileni, V., Pigozzo, J., Ferraresi, V., Nuzzo, C. M. A., Rinaldi, G., Testori, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.007 · Cited by 157 · see citing works

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy

Johnson, B. F., Clay, T. M., Hobeika, A. C., Lyerly, H. K., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.449 · Cited by 119 · see citing works

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma

Yi, J. H., Yi, S. Y., Lee, H., Lee, S. I., Lim, D. H., Kim, J. H., Park, K. W., & Lee, J. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e3283457743 · Cited by 72 · see citing works

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

Alexander, M., Mellor, J. D., McArthur, G. A., & Kee, D. (2014) · The Medical Journal of Australia · doi:10.5694/mja13.10448 · Cited by 62 · see citing works

BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma

Bai, X. L., Mao, L., H., Z., SHENG, X. N., Cui, C.-L., Kong, Y., Dai, J., WANG, X., Li, S., Tang, B. X., et al. (2017) · Neoplasma · doi:10.4149/neo_2017_419 · Cited by 55 · see citing works

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody

Fu, J., Wang, F., Dong, L., Zhang, J., Deng, C.-L., Wang, X., Xie, X.-Y., Zhang, J., Deng, R., Zhang, L., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.161 · Cited by 54 · see citing works

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma

Shoushtari, A. N., Bluth, M. J., Goldman, D. A., Bitas, C., Lefkowitz, R. A., Postow, M. A., Munhoz, R. R., Buchar, G., Hester, R. H., Romero, J. A., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000306 · Cited by 48 · see citing works

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Scorer, P., Scott, M. L. J., Lawson, N. L., Ratcliffe, M., Barker, C., Rebelatto, M. C., & Walker, J. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0725-9 · Cited by 36 · see citing works

Treatment algorithm of metastatic mucosal melanoma.

Wang, X., Si, L., & Guo, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.08.04 · Cited by 33 · see citing works

Management of Metastatic Melanoma in 2018

Kaufman, H. L., Margolin, K. A., & Sullivan, R. J. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0170 · Cited by 33 · see citing works

Clinical and prognostic significance of survivin, AKT and VEGF in primary mucosal oral melanoma.

Simonetti, O., Lucarini, G., Rubini, C., Lazzarini, R., Primio, R. D., & Offidani, A. (2015) · PubMed · Cited by 27 · see citing works

Treatment of KIT-mutated metastatic mucosal melanoma.

Kim, K. B., & Alrwas, A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.08.02 · Cited by 26 · see citing works

Clinical Patterns of Melanoma in Asians

Chan, K. K.-W., Chan, R. C., Ho, R. S. L., & Chan, J. Y. W. (2016) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000000731 · Cited by 24 · see citing works

Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma.

Cui, C., Tang, B., & Guo, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.07.02 · Cited by 16 · see citing works

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 613 · see citing works

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 403 · see citing works

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 355 · see citing works

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 267 · see citing works

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Pan, C.-X., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 245 · see citing works

Molecular Markers and Targets in Melanoma

Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 246 · see citing works

Lactate dehydrogenase: a marker of diminished antitumor immunity

Wilpe, S. V., Koornstra, R. H. T., den Brok, M. H., de Groot, J. W., Blank, C. U., de Vries, I. J. M., Gerritsen, W. R., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 210 · see citing works

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions

Mao, L., Qi, Z., Zhang, L., Guo, J., & Si, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680407 · Cited by 174 · see citing works

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis

Wang, F., He, M.-M., Yao, Y.-C., Zhao, X., Wang, Z., Jin, Y., Luo, H., Li, J., Wang, F., Qiu, M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100383 · Cited by 169 · see citing works

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3922 · Cited by 168 · see citing works

Toripalimab: First Global Approval

Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01076-2 · Cited by 159 · see citing works

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 145 · see citing works

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Zhou, C., Wang, Y., Zhao, J., Chen, G., Liu, Z., Gu, K., Huang, M., He, J., Chen, J., Ma, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3136 · Cited by 127 · see citing works

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117 · see citing works

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Lu, M. S., Zhang, P., Zhang, Y., Li, Z., Gong, J., Li, J., Li, J., Li, Y., Zhang, X., Lü, Z., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4000 · Cited by 111 · see citing works

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 113 · see citing works

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

Zhang, L., Hao, B., Geng, Z., & Geng, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730666 · Cited by 103 · see citing works

Resistance to Molecularly Targeted Therapies in Melanoma

Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021) · Cancers · doi:10.3390/cancers13051115 · Cited by 100 · see citing works

Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3168 · Cited by 98 · see citing works

Designing immunogenic nanotherapeutics for photothermal-triggered immunotherapy involving reprogramming immunosuppression and activating systemic antitumor responses

Wang, J., Chang, Y., Luo, H., Jiang, W., Xu, L., Chen, T., & Zhu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120153 · Cited by 96 · see citing works

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake

Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 91 · see citing works

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Yan, X. Q., Ye, M., Zou, Q., Chen, P., He, Z. S., Wu, B., He, D., He, C. H., Xue, X., Ji, Z., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3108 · Cited by 91 · see citing works

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Zhang, Q., Liu, X., Wei, S., Zhang, L., Tian, Y., Gao, Z., Jin, M., & Yan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751391 · Cited by 77 · see citing works

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.004 · Cited by 70 · see citing works

Head and neck mucosal melanoma: The United Kingdom national guidelines

Nenclares, P., Dafydd, D. A., Bagwan, I., Begg, D., Kerawala, C. J., King, E. V., Lingley, K., Paleri, V., Paterson, G., Payne, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.017 · Cited by 65 · see citing works

Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

Yan, X., Sheng, X., Chi, Z., Si, L., Cui, C., Kong, Y., Tang, B., Mao, L., Wang, X., Lian, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00902 · Cited by 61 · see citing works

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Nakamura, Y., Namikawa, K., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100325 · Cited by 61 · see citing works

Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment

Sergi, M. C., Filoni, E., Triggiano, G., Cazzato, G., Internò, V., Porta, C., & Tucci, M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01453-x · Cited by 61 · see citing works

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis

Steeb, T., Wessely, A., Petzold, A., Kohl, C., Erdmann, M., Berking, C., & Heppt, M. V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.015 · Cited by 59 · see citing works

A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options

Sun, L., Kang, X., Ju, H., Wang, C., Yang, G., Wang, R., & Sun, S. (2023) · Science Advances · doi:10.1126/sciadv.adg6686 · Cited by 58 · see citing works

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review

Li, J., Kan, H., Zhao, L., Sun, Z., & Bai, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922028 · Cited by 57 · see citing works

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

Li, S., Wu, X., Yan, X., Zhou, L., Chi, Z., Si, L., Cui, C., Tang, B., Mao, L., Lian, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004036 · Cited by 56 · see citing works

VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives

Malekan, M., Haass, N. K., Rokni, G. R., Gholizadeh, N., Ebrahimzadeh, M. A., & Kazeminejad, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122563 · Cited by 53 · see citing works

Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies

Rager, T., Eckburg, A., Patel, M., Qiu, R., Gantiwala, S., Dovalovsky, K., Fan, K. D., Lam, K., Roesler, C., Rastogi, A., et al. (2022) · Cancers · doi:10.3390/cancers14153779 · Cited by 52 · see citing works

Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma

Lian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H. Y., Gao, M., Wang, D., Sheng, X., Tian, H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.793 · Cited by 51 · see citing works

Current Trends in Mucosal Melanomas: An Overview

Santeufemia, D. A., Palmieri, G., Miolo, G., Colombino, M., Doro, M. G., Frogheri, L., Paliogiannis, P., Capobianco, G., Madonia, M., Cossu, A., et al. (2023) · Cancers · doi:10.3390/cancers15051356 · Cited by 50 · see citing works

MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response

Zhang, B., Wang, C., Wu, H., Wang, F., Chai, Y., Hu, Y., Wang, B., Zhou, Y. L., Xia, R., Xu, R., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12476 · Cited by 46 · see citing works

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 45 · see citing works

Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor

Li, P., Qin, P., Fu, X., Zhang, G., Yan, X., Zhang, M., Zhang, X., Yang, J., Wang, H., & Ma, Z. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-163 · Cited by 44 · see citing works

Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors

Chambers, A., Kundranda, M. N., Rao, S. K., Mahmoud, F. A., & Niu, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01099-7 · Cited by 43 · see citing works

Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial

Lian, B., Si, L., H., Z., Sheng, X., Kong, Y., Wang, X., Tian, H., Li, K., Mao, L., Bai, X. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.002 · Cited by 42 · see citing works

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective

Jung, S., & Johnson, D. B. (2022) · The Oncologist · doi:10.1093/oncolo/oyac091 · Cited by 41 · see citing works

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Li, X., Li, Y., Lu, W., Chen, M., Ye, W., & Zhang, D. (2019) · Cells · doi:10.3390/cells8121602 · Cited by 38 · see citing works

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

Mao, L., Fang, M., Chen, Y., Wei, X., Cao, J., Lin, J., Zhang, P., Chen, L., Cao, X., Chen, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1528 · Cited by 38 · see citing works

Emerging strategies to treat rare and intractable subtypes of melanoma

Alicea, G. M., & Rebecca, V. W. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12880 · Cited by 37 · see citing works

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

Mao, L., Lian, B., Li, C., Bai, X. L., Zhou, L., Cui, C., Chi, Z., Sheng, X., Wang, X., Tang, B., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1363 · Cited by 36 · see citing works

Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer

Zeng, Y., & Fu, B. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.610661 · Cited by 34 · see citing works

Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice

Huang, H., Zhu, H., Xie, Q., Tian, X., Yang, X., Feng, F., Jiang, Q., Sheng, X., & Yang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.004 · Cited by 33 · see citing works

Evolving Treatment Approaches to Mucosal Melanoma

Zhang, S., Zhang, J.-R., Guo, J., Si, L., & Bai, X. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01225-z · Cited by 25 · see citing works

The role of angiogenesis in melanoma: Clinical treatments and future expectations

Wu, Z., Bian, Y., Chu, T., Wang, Y., Man, S., Song, Y., & Wang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1028647 · Cited by 32 · see citing works

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer

Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., & Li, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276694 · Cited by 32 · see citing works

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial

Cao, Y., Lu, M. S., Sun, Y. L., Gong, J., Li, J., Lü, Z., Li, J., Zhang, X., Li, Y., Peng, Z., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03898-8 · Cited by 32 · see citing works

Toripalimab for the treatment of melanoma

Tang, B., Chi, Z., & Guo, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762561 · Cited by 31 · see citing works

PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation

Siraj, A. K., Parvathareddy, S. K., Pratheeshkumar, P., Divya, S. P., Al-Sobhi, S. S., Al‐Dayel, F., & Al-Kuraya, K. S. (2021) · Cancers · doi:10.3390/cancers13030555 · Cited by 31 · see citing works

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

Comito, F., Pagani, R., Grilli, G., Sperandi, F., Ardizzoni, A., & Melotti, B. (2022) · Cancers · doi:10.3390/cancers14020271 · Cited by 31 · see citing works

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

Wang, X., Wu, X., Yang, Y., Xu, W., Tian, H., Lian, B., Chi, Z., Si, L., Sheng, X., Kong, Y., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.027 · Cited by 29 · see citing works

Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study

Ma, S., Chen, R., Duan, L., Li, C., Yang, T., Wang, J., & Da, Z. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-108 · Cited by 28 · see citing works

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma

Vos, J. L., Traets, J. J. H., Qiao, X., Seignette, I. M., Peters, D. D. G. C., Wouters, M. W. J. M., Hooijberg, E., Broeks, A., van der Wal, J. E., Karakullukçu, B., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179982 · Cited by 27 · see citing works

Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Wang, D., Xu, T., Zhu, H., Dong, J., & Fu, L. (2020) · PubMed Central · Cited by 27 · see citing works

Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis

Zeng, Y., Qiu, Y., Jiang, W., & Fu, B. M. (2022) · Cancers · doi:10.3390/cancers14215415 · Cited by 27 · see citing works

Angiogenesis and Microvascular PermeabilityPreprint

Zeng, Y., & Fu, B. M. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041163 · Cited by 28 · see citing works

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

Indini, A., Roila, F., Grossi, F., Massi, D., & Mandalà, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010147 · Cited by 25 · see citing works

NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis

Tang, W., Li, C., Huang, D., Zhou, S., Zheng, H., Wang, Q., Zhang, X., & Fu, J. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2358551 · Cited by 24 · see citing works

Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis

Wang, X., Montoyo-Pujol, Y. G., Sanchez, S. B., Corpas, G., Castro, A. M., Almazán-Fernández, F. M., Cabrera, T., & López‐Nevot, M. Á. (2021) · Journal of Oncology · doi:10.1155/2021/6610769 · Cited by 24 · see citing works

Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)

Lu, J., Ding, J., Liu, Z., & Chen, T. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5302 · Cited by 24 · see citing works

UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma

Loras, A., Gil‐Barrachina, M., Marqués‐Torrejón, M. Á., Pérez-Pastor, G. M., & Martínez‐Cadenas, C. (2022) · Life · doi:10.3390/life12091339 · Cited by 24 · see citing works

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives

Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 23 · see citing works

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Tang, B., Mo, J., Yan, X., Duan, R., Chi, Z., Cui, C., Si, L., Kong, Y., Mao, L., Li, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.018 · Cited by 22 · see citing works

A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

Zhou, C., Li, Y., Li, J., Song, B., Li, H., Liang, B., Gu, S., Li, H., Chen, C., Li, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0410 · Cited by 22 · see citing works

Multidisciplinary approach and treatment of acral and mucosal melanoma

Fortuna, A., & Amaral, T. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1340408 · Cited by 22 · see citing works

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes

Shan, Z., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1441410 · Cited by 22 · see citing works

Immunotherapy for gastric cancer: Advances and challenges

Zhang, P., Zhang, C., Li, X., Chang, C., Gan, C., Ye, T., & Cao, D. (2024) · MedComm – Oncology · doi:10.1002/mog2.92 · Cited by 21 · see citing works

Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model

Jiang, J., Li, D., Liu, T., Xia, L., Guo, X., Meng, X., Liu, F., Wang, F., Yang, Z., & Zhu, H. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127901 · Cited by 20 · see citing works

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma

Zhao, L., Ren, Y., Zhang, G., Zheng, K., Wang, J., Sha, H., Zhao, M., Huang, R., Kang, D., Su, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008611 · Cited by 21 · see citing works

Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab

Wang, S., Zhu, H., Ding, J., Wang, F., Meng, X., Ding, L., Zhang, Y., Li, N., Yao, S., Sheng, X., et al. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003520 · Cited by 20 · see citing works

Melanoma Tumour Vascularization and Tissue-Resident Endothelial Progenitor Cells

Hashemi, G., Dight, J., Khosrotehrani, K., & Sormani, L. (2022) · Cancers · doi:10.3390/cancers14174216 · Cited by 18 · see citing works

Single-cell sequencing depicts tumor architecture and empowers clinical decision in metastatic conjunctival melanoma

Shi, H., Tian, H., Zhu, T.-Y., Liao, Q., Liu, C., Yuan, P., Li, Y.-Y., Yang, J., Zong, C., Jia, S., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00683-y · Cited by 19 · see citing works

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 19 · see citing works

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Shi, J., Jiao, T., Guo, Q., Weng, W., Ma, L., Zhang, Q., Wang, L., Zhang, J., Chen, C., Huang, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1356 · Cited by 18 · see citing works

Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis

Teo, A. Y. T., Yau, C. E., Low, C. E., Pereira, J. V., Ng, J. Y. X., Soong, T. K., Lo, Y. T., & Yang, V. S. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102870 · Cited by 17 · see citing works

Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy

Huang, F., Li, J., Wen, X., Zhu, B., Liu, W., Wang, J., Jiang, H., Ding, Y., Li, D., & Zhang, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-13391-y · Cited by 17 · see citing works

Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

Jaeger, Z. J., Raval, N. S., Maverakis, N., Chen, D. Y., Ansstas, G., Hardi, A., & Cornelius, L. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1090737 · Cited by 16 · see citing works

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review

Jeong, Y. J., Thompson, J. F., & Ch’ng, S. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-16 · Cited by 16 · see citing works

Therapeutic Approaches to Mucosal Melanoma

Lian, B., & Guo, J. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473858 · Cited by 15 · see citing works

Melanoma-derived extracellular vesicles transfer proangiogenic factors

Surman, M., Przybyło, M., & Wilczak, M. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.055449 · Cited by 15 · see citing works

Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score

Shen, K., Song, W., Wang, H., Wang, L., Yang, Y., Hu, Q., Ren, M., Gao, Z., Wang, Q., Zheng, S., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01678-6 · Cited by 14 · see citing works

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma

Shui, L., Cheng, K., Li, X., Shui, P., Li, S., Peng, Y., Li, J., Guo, F., Cheng, Y., & Cao, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01127 · Cited by 14 · see citing works

Primary Malignant Melanoma of the Genitourinary System: A Systemic Review and Report of Eight Cases

Khayyat, A., Pour, M. A. E., Mousavi, S., Khalili-Toosi, A.-R., & Amin, A. (2022) · Cureus · doi:10.7759/cureus.30444 · Cited by 13 · see citing works

Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma

Xu, K., Wu, H., Zhou, C., Bao, Y., Yu, M., Zhang, L., & Li, X. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01540-w · Cited by 13 · see citing works

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC

Wang, Y., Zhang, N., Xue, J., Zhu, C., Wang, Y., Zhang, L., Yang, X., Wang, H., Wang, S., Chao, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084843 · Cited by 12 · see citing works

Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma

Du, Y., Dai, J., Mao, L., Wei, X., Bai, X. L., Chen, L., Lin, J., Chi, Z., Cui, C., Sheng, X., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19467 · Cited by 12 · see citing works

Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma

Chacon, A. C., Melucci, A. D., Qin, S. S., & Prieto, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063228 · Cited by 12 · see citing works

Immune checkpoint inhibitor‐based therapy for advanced acral and mucosal melanoma

Mori, T., Izumi, T., Doi, R., Kamimura, A., Takai, S., Teramoto, Y., & Nakamura, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14725 · Cited by 12 · see citing works

PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer

Parvathareddy, S. K., Siraj, A. K., Ahmed, S. O., Ghazwani, L. O., Aldughaither, S. M., Al‐Dayel, F., Tulbah, A. M., Ajarim, D. S., & Al-Kuraya, K. S. (2021) · Cells · doi:10.3390/cells10020229 · Cited by 12 · see citing works

Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma

Wu, Y., Wei, D., Ren, G., & Guo, W. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04090-2 · Cited by 11 · see citing works

Management of Noncutaneous Melanomas

Lee, A. Y., & Berman, R. S. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.02.004 · Cited by 11 · see citing works

Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data

Zhang, X., Jin, F., Jiang, S., Cao, J., Meng, Y., Xu, Y., ChunmengWang, Chen, Y., Yang, H., Kong, Y., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01172-9 · Cited by 11 · see citing works

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma

Anko, M., Kobayashi, Y., Banno, K., & Aoki, D. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050403 · Cited by 10 · see citing works

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b TrialPreprint

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3320203

Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.10007 · Cited by 12 · see citing works

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Tang, B., Mo, J., Yan, X., Duan, R., Chi, Z., Cui, C., Si, L., Kong, Y., Mao, L., Li, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.018 · Cited by 22 · see citing works

Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma

Lochrin, S. E., Kalvin, H. L., Chen, M. F., Smithy, J. W., Momtaz, P., Postow, M. A., Station, S., Hochreiter, C., Panageas, K. S., Yeh, R., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-1089

Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.

Cui, C., Lian, B., Sheng, X., Xu, H., Si, L., Chi, Z., Yang, Y., Wang, X., Li, C., Mao, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.9512 · Cited by 6 · see citing works